ITIH5 showed significant increases in methylation level for breast cancer patients (4.49% versus 5.93%, p = 0.0085) and DCIS patients (4.49% versus 6.87%, p < 0.0001, Figure 2D). This evidence concerns the gene ITIH5 and ductal breast carcinoma in situ.